Nimpa Marcellin Mengouo, Razafiarivao Noёline Ravelomanana, Robinson Annick, Fidiniaina Mamy Randriatsarafara, Razafindratsimandresy Richter, Masembe Yolande Vuo, Bodohanta Christiane Ramonjisoa, Kouadio Isidore Koffi, Nyazy Issa Kana Kode, Simpore Moussa, Ndiaye Charlotte Faty, Okeibunor Joseph Chukwudi
World Health Organization Regional Office for Africa, Congo.
Faculté de Médécine d'Anatanarivo, Madagascar.
J Immunol Sci. 2021 Apr 13;Spec Issue(2):1102. doi: 10.29245/2578-3009/2021/S2.1102.
In 1988, the World Health Assembly launched the Global Polio Eradication Initiative. WHO AFRO is close to achieve this goal with the last wild poliovirus detected in 2014 in Borno States in Nigeria. The certification of the WHO African Region requires that all the 47 member states meet the critical indicators for a polio free status. Madagascar started implementing polio eradication activities in 1996 and was declared polio free in June 2018 in Abuja. This study describes the progress achieved towards polio eradication activities in Madagascar from 1977-2017 and highlights the remaining challenges to be addressed.
Data were collected from the national routine immunization services, Country Acute Flaccid surveillance databases and national reports of SIAS and Mop Up campaign. Country complete polio and immunization related documentation provided detailed historical information's.
From 1997 to 2017, Madagascar reported one wild poliovirus (WPV) outbreak and four circulating Vaccine Derived Polio Virus (cVDPV) oubreaks with a total of 21 polioviruses (1 WPV and 21 cVDPV). The last WPV and cVDPV were notified in 1997 in Antananarivo and 2015 in Sakaraha health districts respectively. Madagascar met the main polio surveillance indicators over the last ten years and made significant progress following the last cVDPV2 outbreak in 2014 -2015. In addition, the country successfully implemented the switch from trivalent Oral Polio Vaccine (tOPV) to bivalent Oral Polio vaccine (bOPV) and containment activities. Environmental Surveillance established since 2015 did not reveal any poliovirus. The administrative coverage of the 3rd dose of oral polio vaccine (OPV3) varied across the years from 55% in 1991 to a maximum of 95% in 2007 before a progressive decrease to 86% in 2017. The percentage of AFP cases with more than 3 doses of oral polio vaccines increased from 56% in 2014 to 88% in 2017. A total of 19 supplementary immunization activities (SIA) were conducted in Madagascar from 1997 to 2017, among which 3 were subnational immunization days (sNID) and 16 were national immunization days (NIDs). Poor routine coverage contributed to the occurrence of cVDPC outbreaks in the country; addressing this should remain a key priority for the country to maintain the polio free status.From 2015 to June 2017, Madagascar achieved the required criteria leading to the acceptance of the country's polio-free documentation in June 2018 by ARCC. However, continuous efforts will be needed to maintain a highly sensitive polio surveillance system with emphasis on security compromised areas. Finally strengthening the health system and governance at all levels will be necessary if these achievements are to be sustained.
High national political commitment and support of the Global Polio Eradication Partnership were critical for Madagascar to achieve polio free status. Socio-political instability, weakness of the health system, sub-optimal routine immunization performance, insufficient SIA quality and existing security compromised areas remain critical program challenges to address in order to maintaining the polio free status. Continuous high-level advocacy should be kept in order to ensure that new government authorities maintain polio eradication among the top priorities of the country.
1988年,世界卫生大会发起了全球根除脊髓灰质炎行动。世卫组织非洲区域办事处已接近实现这一目标,2014年在尼日利亚博尔诺州发现了最后一例野生脊髓灰质炎病毒。世卫组织非洲区域的认证要求47个成员国全部达到无脊髓灰质炎状态的关键指标。马达加斯加于1996年开始实施根除脊髓灰质炎活动,并于2018年6月在阿布贾宣布成为无脊髓灰质炎国家。本研究描述了1977年至2017年马达加斯加在根除脊髓灰质炎活动方面取得的进展,并强调了仍需应对的挑战。
数据收集自国家常规免疫服务、国家急性弛缓性麻痹监测数据库以及扫荡式免疫和 mop up 活动的国家报告。该国完整的脊髓灰质炎和免疫相关文件提供了详细的历史信息。
1997年至2017年,马达加斯加报告了1起野生脊髓灰质炎病毒(WPV)疫情和4起循环疫苗衍生脊髓灰质炎病毒(cVDPV)疫情,共有21株脊髓灰质炎病毒(1株WPV和20株cVDPV)。最后1例WPV和cVDPV分别于1997年在塔那那利佛和2015年在萨卡拉哈卫生区被通报。马达加斯加在过去十年中达到了主要的脊髓灰质炎监测指标,并在2014 - 2015年最后一次cVDPV2疫情后取得了显著进展。此外,该国成功实施了从三价口服脊髓灰质炎疫苗(tOPV)到二价口服脊髓灰质炎疫苗(bOPV)的转换及控制活动。自2015年起开展的环境监测未发现任何脊髓灰质炎病毒。口服脊髓灰质炎疫苗第3剂(OPV3)的行政覆盖率多年来有所不同,从1991年的55%到2007年的最高95%,之后逐步降至2017年的86%。接种过3剂以上口服脊髓灰质炎疫苗的急性弛缓性麻痹(AFP)病例百分比从2014年的56%增至2017年的88%。1997年至2017年马达加斯加共开展了19次补充免疫活动(SIA),其中3次是省级免疫日(sNID),16次是全国免疫日(NID)。常规免疫覆盖率低导致该国发生cVDPC疫情;解决这一问题应仍是该国维持无脊髓灰质炎状态的关键优先事项。2015年至2017年6月,马达加斯加达到了相关要求标准,从而在2018年6月被非洲区域认证委员会接受了该国的无脊髓灰质炎文件。然而,仍需持续努力维持高度敏感的脊髓灰质炎监测系统,重点关注安全受影响地区。最后,如果要维持这些成果,加强各级卫生系统和治理将是必要的。
国家的高度政治承诺以及全球根除脊髓灰质炎伙伴关系的支持对马达加斯加实现无脊髓灰质炎状态至关重要。社会政治不稳定、卫生系统薄弱、常规免疫表现欠佳、补充免疫活动质量不足以及现有的安全受影响地区仍是维持无脊髓灰质炎状态需要应对的关键项目挑战。应持续进行高层倡导,以确保新的政府当局将根除脊髓灰质炎维持在该国的首要优先事项之中。